Syncor to Sell or Close Home-Infusion Facilities

Syncor International Corp. said it plans to shed its home-infusion unit, which accounts for about 6% of its business.

Syncor’s total revenue in its fiscal year ended May 31, 1992, was $210.2 million. The company primarily provides radiopharmaceuticals and other specialty drugs, such as those for diagnostic imaging, to hospitals and clinics.

The Chatsworth-based company plans to close four of its home-infusion sites--which provide intravenous-therapy products for patients at home--and to sell the remaining nine facilities.

Syncor also announced that for the past 15 months, it has been developing plans for a national pharmacy system to deliver therapies to oncologists, or cancer specialists. Pilot tests of the system will continue into Syncor’s 1994 fiscal year.